Biotech Stock Roundup: ARIAD Down On Drug Pricing Tweet, Regeneron Study On Clinical Hold
Zacks Investment Research | Oct 18, 2016 10:11PM ET
Once again, a single tweet on drug pricing resulted in weakness in the biotech sector with ARIAD (NASDAQ:ARIA) losing ground on a tweet regarding the company’s price hikes for cancer drug, Iclusig. Meanwhile, Regeneron (NASDAQ:REGN) suffered a pipeline setback with the FDA putting a clinical hold on one of its studies.
Recap of the Week’s Most Important Stories
ARIAD Shares Fall on Sanders Tweet: Shares of ARIAD declined 14.8% after Senator Bernie Sanders tweeted on the company’s price hike of leukemia drug Iclusig. The tweet “Drug corporations' greed is unbelievable. Ariad has raised the price of a leukemia drug to almost $199,000 a year” was in response to an article according to which ARIAD had raised the price of Iclusig the fourth time this year with the treatment now costing $16,561 per month, or almost $199,000 per year, excluding discounts or rebates. Drug pricing issues are not something new but with the Presidential election round the corner, concerns regarding the implementation of new drug pricing policies are picking up.
Regeneron-Teva Study on Clinical Hold: Regeneron and partner Teva were hit by a clinical hold on their experimental pain treatment, fasinumab. The FDA placed a phase IIb study in patients with chronic low back pain on clinical hold and asked for the study protocol to be amended following the discovery of adjudicated arthropathy in a patient receiving high dose fasinumab – the patient had advanced osteoarthritis at study entry.
Fasinumab is an investigational nerve growth factor (NGF) antibody. Dosing in the study has been stopped and Teva and Regeneron are now planning a pivotal phase III study for chronic low back pain excluding patients with advanced osteoarthritis.
Meanwhile, the companies plan to study only lower doses in the phase III osteoarthritis pain program as the incidence of adjudicated arthropathies was found to be potentially dose-dependent, with a higher rate in the higher dose groups. Shares of both Regeneron and Teva were down on the fasinumab update (Read more: Ocular's Stock Jumps on Collaboration with Regeneron ).
PTC Plunges on Translarna Update: PTC Therapeutics’ (NASDAQ:PTCT) shares declined almost 40% with the FDA’s Office of Drug Evaluation I (ODE-I) denying the company's first appeal of the refuse to file letter for its Duchenne muscular dystrophy treatment, Translarna, earlier this year. The company said that it intends to appeal to the next supervisory level of the FDA and believes that multiple cycles of appeals to progressively higher levels of the FDA may be required.
The Medicines Co. Gains on PCSK9 Data: The Medicines Company’s (NASDAQ:MDCO) shares were up on positive top-line results from a Day 90 interim analysis of an ongoing phase II study (ORION-1) being conducted on PCSK9si, an investigational PCSK9 inhibitor. The company said that the safety and efficacy data support a triannual, and potentially biannual, low volume subcutaneous dose regimen, for treating patients with hypercholesterolemia. Currently approved PCSK9 inhibitors include Sanofi (PA:SASY) and Regeneron’s Praluent and Amgen’s Repatha. Repatha gained FDA approval for a new, monthly single-dose administration option in July this year.
Get The News You Want
Performance
Medical - Biomedical and Genetics Industry Price Index
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.